Next-Gen Sequencing Matches Blood Group Antigens for Transfusion
|
By LabMedica International staff writers Posted on 26 Sep 2019 |

Image: The ID Core XT BLOODchip is a molecular-based assay used in blood transfusion medicine to help determine blood compatibility and could supplement the classical blood match methodology (Photo courtesy of Progenika Biopharma SA).
Transfusion is the procedure of introducing donor material with unknown blood cell antigens into the recipient’s circulatory system. The recipient’s immune system recognizes foreign antigens, produces specific antibodies and sensitization (alloimmunization) occurs.
To date, more than 300 red blood cell (RBC) and 33 human platelet antigens (HPA) have been described. Extended antigen typing is time-consuming, serological methods are costly and depend on the availability of reagents for antigen detection. The procedure is usually performed in reference laboratories, which complicates and delays the delivery of blood for transfusion.
Scientists at the Institute of Hematology and Transfusion Medicine (Warsaw, Poland) have reviewed the advances in applying next-generation sequencing (NGS) to transfusion medicine for the purpose of genotyping alleles encoding clinically important red blood cell and platelet antigens. The currently available technologies allow various levels of sequencing; either the whole genome (WGS), coding regions, exons (WES) or only selected genes or regions of interest. NGS technology significantly reduces the cost of testing. It has been successfully implemented in transplantation medicine for testing donors’ genotypes of HLA antigens in high-throughput mode. Over 9,000 HLA alleles for over 500 individuals can be identified per run.
NGS is particularly effective for finding unknown variations responsible for different phenotypes in patients with antibodies of unknown specificity because it enables screening of the whole genome, exome or particular genes and finding an unknown or rare variant. Recent studies have confirmed NGS effectiveness in resolving the molecular background of orphan antigens with an as yet unknown genetic basis. NGS is also effective in reducing the risk of post-transfusion alloimmunization since the huge capacity of one investigation enables the immediate and cost-effective determination of all RBC and platelet antigen genotypes. Study results support extended profiling of donors and patients for the best prophylactic antigen matching to prevent alloimmunization.
The application of NGS technology for blood typing contributes to the following aspects of patient care: Prevention of alloimmunization in sickle cell disease (SCD) and other transfusion-dependent patients; faster and cheaper diagnostics in the case of patients with unexplained, complex serological results; the huge capacity of the NGS investigations makes this technology an ideal tool for mass screening of blood donors for all clinically important antigens and also to detect individuals with rare blood group antigens in various ethnic groups; this facilitates access to compatible donors for alloimmunised patients.
The authors concluded that the future of NGS as a supplementary test used to provide highly compatible blood as well as to reduce the risk of patient’s alloimmunization and this is part of personalized medicine. The study was published on September 3, 2019, in the journal International Journal of Clinical Transfusion Medicine.
Related Links:
Institute of Hematology and Transfusion Medicine
To date, more than 300 red blood cell (RBC) and 33 human platelet antigens (HPA) have been described. Extended antigen typing is time-consuming, serological methods are costly and depend on the availability of reagents for antigen detection. The procedure is usually performed in reference laboratories, which complicates and delays the delivery of blood for transfusion.
Scientists at the Institute of Hematology and Transfusion Medicine (Warsaw, Poland) have reviewed the advances in applying next-generation sequencing (NGS) to transfusion medicine for the purpose of genotyping alleles encoding clinically important red blood cell and platelet antigens. The currently available technologies allow various levels of sequencing; either the whole genome (WGS), coding regions, exons (WES) or only selected genes or regions of interest. NGS technology significantly reduces the cost of testing. It has been successfully implemented in transplantation medicine for testing donors’ genotypes of HLA antigens in high-throughput mode. Over 9,000 HLA alleles for over 500 individuals can be identified per run.
NGS is particularly effective for finding unknown variations responsible for different phenotypes in patients with antibodies of unknown specificity because it enables screening of the whole genome, exome or particular genes and finding an unknown or rare variant. Recent studies have confirmed NGS effectiveness in resolving the molecular background of orphan antigens with an as yet unknown genetic basis. NGS is also effective in reducing the risk of post-transfusion alloimmunization since the huge capacity of one investigation enables the immediate and cost-effective determination of all RBC and platelet antigen genotypes. Study results support extended profiling of donors and patients for the best prophylactic antigen matching to prevent alloimmunization.
The application of NGS technology for blood typing contributes to the following aspects of patient care: Prevention of alloimmunization in sickle cell disease (SCD) and other transfusion-dependent patients; faster and cheaper diagnostics in the case of patients with unexplained, complex serological results; the huge capacity of the NGS investigations makes this technology an ideal tool for mass screening of blood donors for all clinically important antigens and also to detect individuals with rare blood group antigens in various ethnic groups; this facilitates access to compatible donors for alloimmunised patients.
The authors concluded that the future of NGS as a supplementary test used to provide highly compatible blood as well as to reduce the risk of patient’s alloimmunization and this is part of personalized medicine. The study was published on September 3, 2019, in the journal International Journal of Clinical Transfusion Medicine.
Related Links:
Institute of Hematology and Transfusion Medicine
Latest Hematology News
- Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
- Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
- Study Confirms Blood Products Remain Viable After Three Weeks in the Arctic
- New Reference Ranges Clarify Normal Neutrophil Counts in Duffy-Null Patients
- Newly Certified FISH Probes Support Cytogenetic Testing in Blood Cancers
- Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification
- New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL
- Handheld Point-of-Care Test Aims to Enable Rapid Coagulation Assessment in Trauma
- New Myelofibrosis Guidelines Recommend Expanded Genetic Testing at Diagnosis
- New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
- New Automated Hemostasis Systems Become Available Across US Laboratories
- Updated Ferritin Thresholds Improve Detection of Iron Deficiency
- Variation in AML Residual Disease Testing Prompts Push for Standardization
- Hidden Molecular Mechanism Behind HIT Blood-Clotting Disorder Revealed
- Borderline Anemia May Carry Higher Risk Than Current Thresholds Suggest
- Biomarker-Guided Framework Aims to Guide Mantle Cell Lymphoma Therapy
Channels
Clinical Chemistry
view channel
Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine
Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more
Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research
Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more
Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read moreMolecular Diagnostics
view channel
Protein-Based Classifier Shows Promise for Predicting Melanoma Treatment Outcomes
Immune checkpoint inhibitors have improved melanoma treatment and extended survival over the past 15 years. However, many patients do not respond, and reliable biomarkers for predicting treatment response... Read more
Liquid Biopsy Gains FDA Approval to Guide Breast Cancer Combination Therapy
Estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer accounts for approximately 70% of cases. Acquired ESR1 mutations can cause resistance to endocrine... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
New WHO Tools Address Gaps in Antimicrobial Resistance Testing
Antimicrobial resistance (AMR) is a growing global health threat, making infections increasingly difficult to diagnose and treat as they become resistant to standard antibiotics. Its spread is driven partly... Read more
Complete Malaria Genomes Could Improve Species Identification and Surveillance
Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read morePathology
view channel
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil
Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more







